Blog

Is All Privileged Client-Provider Email Cataloged by The US Government and Accessible by Request?

February 24, 2015 / in Blog / by Zafar Khan, RPost CEO

All service providers (such as lawyers, doctors, accountants, financial advisors, etc.) who believe their communications with clients are private — and in some situations, privileged — should take note. Conversely, all clients who believe their communications with trusted service providers are private should also take note.

Now is the Time for Secure Emails, Digital Signatures and Electronic Contracts – A Legal Perspective

February 24, 2015 / in Blog / by Zafar Khan, RPost CEO

Robert Bond, one of the world’s premier legal experts in data privacy and information security, just hosted an exclusive webinar where he presented a number of practical reasons why every legal professional needs to do more than just use standard Microsoft Outlook or other basic technologies when corresponding with clients, other legal counsel, the courts […]

RPost Builds the Post Office into Gmail

September 29, 2014 / in Blog / by Zafar Khan, RPost CEO

With RMail for Gmail, Millions of Users Can Now Send Registered Email Messages from their Gmail Compose Interface Stockholm, Sweden, and Los Angeles, CA —September 23, 2014– Today, RPost announced the availability of its heavily-anticipated RMail extension for Gmail for national postal operators worldwide. RMail® for Gmail creates an easy method for national postal operators […]

Eight RPost Patents Valid after Post-Grant Challenges

August 29, 2014 / in Blog / by Zafar Khan, RPost CEO

The Leahy–Smith America Invents Act (AIA), signed into law in 2011, has created new opportunities for those accused of patent infringement to challenge the validity of granted patents, with the institution of new “post-grant” proceedings.

RPost Services Support Compliance with New FDA Guidelines On 21 CFR Part 11

February 14, 2014 / in Blog / by Zafar Khan, RPost CEO

The Food and Drug Administration (FDA) has published guidance for compliance with specific regulations in 21 CFR Part 11. This guidance is intended to describe the FDA’s current thinking regarding the scope and application of part 11 of Title 21 of the Code of Federal Regulations; Electronic Records; Electronic Signatures (21 CFR Part 11).